航空航天医学杂志
航空航天醫學雜誌
항공항천의학잡지
AEROSPACE MEDICINE
2014年
4期
433-434
,共2页
李思%洪珞珈%展昭民%梁红%唐庆华%赵东陆%于洋%杨秀丽%曹志坚%刘洋
李思%洪珞珈%展昭民%樑紅%唐慶華%趙東陸%于洋%楊秀麗%曹誌堅%劉洋
리사%홍락가%전소민%량홍%당경화%조동륙%우양%양수려%조지견%류양
重组人血小板生成素(rhTPO)%重组人白介素-11(rhIL-11)%血小板减少症%急性白血病%化疗
重組人血小闆生成素(rhTPO)%重組人白介素-11(rhIL-11)%血小闆減少癥%急性白血病%化療
중조인혈소판생성소(rhTPO)%중조인백개소-11(rhIL-11)%혈소판감소증%급성백혈병%화료
rhTPO%rhIL-11%Thrombocytopenia%Acute leukemia%Chemotherapy
目的：评价重组人血小板生成素（ rhTPO）治疗白血病化疗后血小板（ PLT）减少症的疗效和安全性。方法96例白血病患者随机分为治疗组（重组人血小板生成素，rhTPO）与对照组（重组人白介素-11，rhIL-11），分别皮下注射，观察外周血小板的变化。结果治疗组血小板的最低值和恢复的最高值显著高于对照组；治疗组的PLT ＜50×109 L-1的持续时间、恢复到70×109 L-1和125×109 L-1所需要的时间，显著低于对照组所需时间；治疗组不良反应少且较轻微。结论重组人血小板生成素（ rhTPO）治疗急性白血病化疗后的血小板减少症疗效显著且安全性好。
目的：評價重組人血小闆生成素（ rhTPO）治療白血病化療後血小闆（ PLT）減少癥的療效和安全性。方法96例白血病患者隨機分為治療組（重組人血小闆生成素，rhTPO）與對照組（重組人白介素-11，rhIL-11），分彆皮下註射，觀察外週血小闆的變化。結果治療組血小闆的最低值和恢複的最高值顯著高于對照組；治療組的PLT ＜50×109 L-1的持續時間、恢複到70×109 L-1和125×109 L-1所需要的時間，顯著低于對照組所需時間；治療組不良反應少且較輕微。結論重組人血小闆生成素（ rhTPO）治療急性白血病化療後的血小闆減少癥療效顯著且安全性好。
목적：평개중조인혈소판생성소（ rhTPO）치료백혈병화료후혈소판（ PLT）감소증적료효화안전성。방법96례백혈병환자수궤분위치료조（중조인혈소판생성소，rhTPO）여대조조（중조인백개소-11，rhIL-11），분별피하주사，관찰외주혈소판적변화。결과치료조혈소판적최저치화회복적최고치현저고우대조조；치료조적PLT ＜50×109 L-1적지속시간、회복도70×109 L-1화125×109 L-1소수요적시간，현저저우대조조소수시간；치료조불량반응소차교경미。결론중조인혈소판생성소（ rhTPO）치료급성백혈병화료후적혈소판감소증료효현저차안전성호。
Objce tive To evaluate the efficacy and safety of recombinant human thrombopoietin ( rhTPO) compared with recombinant human interleukin 11(rhIL-11)in the treatment of chemotherapy induced thrombocytopenia in patients with leukemia.Methods Ninety -six patients with leukemia were divided into trial and control groups random-ly.Patients in trial group were given rhTPO subcutaneously and patients in control group were given rhIL -11 subcutane-ously.The peripheral platelet count was observed consecutively.Results The mean minimal and maxima platelet count in the trial group was significantly higher than the control group.The time of platelet count less than 50 ×109 L-1 and needed to achieve a level to 70 ×109 L-1 and 125 ×109 L-1 in the trial group were significantly shorter than in the con-trol group.Slight adverse reaction was observed in the trial group.Conc lusions rhTPO is effective and safety in treat-ment of acute leukemia chemotherapy induced thrombocytopenia.
